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Abstract
Background: Hepatocellular carcinoma (HCC) is the most common tumor in the adult liver, with
high relapse and mortality rates despite diverse treatment modalities. In this study, nicotinamide
N-methyltransferase (NNMT), a key enzyme in drug metabolism, was investigated as a potential
prognostic factor.
Methods: Frozen tumors and non-cancerous surrounding tissues from 120 patients with primary
HCC were studied. Expressions of NNMT and internal control genes were measured by real-time
reverse-transcription PCR (RT-PCR). The relationship of NNMT mRNA level with
clinicopathologic parameters and clinical outcome was evaluated.
Results:  NNMT mRNA level is markedly reduced in HCCs compared to non-cancerous
surrounding tissues (P < 0.0001), and NNMT expression in tumors was significantly correlated with
tumor stage (P = 0.010). Moreover, stratification of patients based on tumor NNMT mRNA levels
revealed that the patients who expressed higher NNMT mRNA levels tended to have a shorter
overall survival (OS) time (P = 0.053) and a significantly shorter disease-free survival (DFS) time (P
= 0.016). Both NNMT expression (P = 0.0096) and tumor stage (P = 0.0017) were found to be
significant prognostic factors for DFS in a multivariate analysis.
Conclusion: The results of this study indicated that NNMT gene expression is associated with
tumor stage and DFS time in HCC cases. Because of the broad substrate specificity of NNMT,
which could alter the efficacy and adverse effects of chemotherapy, NNMT merits further
investigation regarding its role as a prognostic factor with a larger cohort of HCC patients.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the most common form of
liver cancer, being responsible for 80% of primary malig-
nant tumors in adults. HCC causes more than 600,000
deaths annually worldwide [1] and its endemic preva-
lence in Asia, including South Korea, makes HCC one of
the top causes of death in this region. HCC is a type of
tumor that is highly resistant to available chemotherapeu-
tic agents, administered either alone or in combination
[2]. Thus, in many cases, no effective therapy can be
offered to patients with HCC. Therefore, it is of vital
importance to identify important prognostic factors and
novel molecular targets of HCC to develop targeted thera-
pies, ultimately advancing therapeutic strategies of HCC
in general.
Current evidence indicates that the precancerous liver and
the early stages in HCC development are characterized by
certain common traits governed by both genetic and epi-
genetic mechanisms [3,4]. These include the alteration of
numerous signaling pathways leading to autonomous
and deregulated cell proliferation and resistance to cell
death [4-7]. Therefore, it is important to better understand
the roles of deregulated genes in hepatocellular carcino-
genesis. Derangements in various methylation processes
in liver diseases have been identified [8,9], including
increased nicotinamide methylation in cirrhotic patients
[10]. Nicotinamide N-methyltransferase (NNMT) cata-
lyzes the N-methylation of nicotinamide, pyridines, and
other structural analogues [11]. It is involved in the
biotransformation of many drugs and xenobiotic com-
pounds. Although several studies indicated differential
expression of NNMT in HCC specimens [12-15], the clin-
copathologic relevance of NNMT expression has not been
fully investigated.
The aim of the present investigation was to examine
whether NNMT expression could be used to predict the
clinical course of HCC. Using a real-time RT-PCR analysis
of NNMT gene expression, we found significant correla-
tion between NNMT mRNA levels and poor prognosis of
HCC. Thus, potential biological changes related to NNMT
gene expression require further study, as they may have
implications in predicting clinical outcome and choosing
treatment modalities, due to the central role of NNMT in
biotransformation and detoxification.
Methods
Patients and tissue samples
HCC (T) and corresponding non-cancerous hepatic tis-
sues (NT) were obtained with informed consent from 120
patients who underwent curative hepatectomy for pri-
mary HCC between 2001 and 2006 in the Department of
Surgery, Samsung Medical Center, Korea. The study proto-
col was approved by the Institutional Review Board of
Samsung Medical Center. Complete clinical data were
available in all 120 cases (median follow-up, 50 months;
range, 3 – 92 months). The patients, ranging in age from
21 to 78 years (mean, 51.3 years) and having adequate
liver function reserve, had survived for at least 2 months
after hepatectomy, and none received treatment prior to
surgery such as transarterial chemoembolization or radi-
ofrequency ablation. Clinicopathologic features of the
120 HCCs in this study are described in Table 1. Surgically
resected specimens were partly embedded in paraffin after
fixation in 10% formalin for histological processing and
partly immediately frozen in liquid nitrogen and stored at
-80°C. All available hematoxylin and eosin stained slides
were reviewed. The tumor grading was based on the crite-
ria proposed by Edmondson and Steiner (I, well differen-
tiated; II, moderately differentiated; III, poorly
differentiated; IV, undifferentiated) [16]. The conven-
tional TNM system outlined in the cancer staging manual
(6th ed.) by the American Joint Committee on Cancer
(AJCC) was used in tumor staging.
RNA extraction and cDNA synthesis
Total RNA was extracted from cancerous and surrounding
non-cancerous frozen tissues using an RNeasy minikit
(Qiagen, Germany) according to the manufacturer's
instructions. The integrity of all tested total RNA samples
was verified using a Bioanalyzer 2100 (Agilent Technolo-
gies, United States). DNase I treatment was routinely
included in the extraction step. Residual genomic DNA
contamination was assayed by a quantitative real-time
PCR assay for GAPDH DNA and samples with contami-
nating DNA were re-subjected to DNase I treatment and
assayed again. Samples containing 4 μg of total RNA were
incubated with 2 μl of 1 μM oligo d(T)18 primer (Gen-
otech, Korea) at 70°C for 7 min and cooled on ice for 5
min. The enzyme mix was separately prepared in a total
volume of 11 μl by adding 2 μl of 0.1 M DTT (Duchefa,
Netherlands), 2 μl of 10× reverse-transcription buffer, 5 μl
of 2 mM dNTP, 1 μl of 200 U/μl MMLV reverse-tran-
scriptase, and 1 μl of 40 U/μl RNase inhibitor (Enzynom-
ics, Korea). After adding the enzyme mix to the annealed
total RNA sample, the reaction was incubated for 90 min
at 42°C prior to heat inactivation of reverse-transcriptase
at 80°C for 10 min. The cDNA samples were brought up
to a final volume of 400 μl by the addition of diethylpy-
rocarbonate (DEPC)-treated water.
Quantitative real-time PCR
Real-time PCR amplifications were carried out in 384 well
plates according to the instructions of the manufacturer,
using Applied Biosystems PRISM 7900HT instruments.
The real-time PCR analysis was performed in a total vol-
ume of 10 μl with 5 μl of 2× Taqman gene expression mas-
ter mix (Applied Biosystems, United States), 1 μl each ofJournal of Experimental & Clinical Cancer Research 2009, 28:20 http://www.jeccr.com/content/28/1/20
Page 3 of 9
(page number not for citation purposes)
Table 1: Relations between NNMT mRNA levels and clinicopathologic features in HCC
All patients (n = 120)
Clinicopathologic parameters High NNMT (n = 48)
Copy number ratio
≥ 4.40
Low NNMT (n = 72)
Copy number ratio
< 4.40
P value
Age 0.730
< 55 years 31 43
≥ 55 years 17 29
Gender 0.758
Male 38 54
Female 10 18
HbsAg 0.885
Absent 8 14
Present 40 58
HCV 0.823
Absent 45 67
Present 3 5
Liver cirrhosis 0.852
Absent 25 40
Present 23 32
Tumor stage 0.010
I2 3 2 3
II 9 33
III & IV 16 16
AFP level 0.314
< 100 ng/ml 28 34
≥ 100 ng/ml 20 38
Tumor size 0.733
< 5 cm 27 44
≥ 5 cm 21 28
Edmondson grade 0.368Journal of Experimental & Clinical Cancer Research 2009, 28:20 http://www.jeccr.com/content/28/1/20
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5 μM forward and reverse primers and 1 μM probe (Gen-
otech), and 2 μl of cDNA (or water as a control, which was
always included). The amplification steps were as follows:
an initial denaturation step, 95°C for 10 min, followed by
40 cycles of denaturation at 95°C for 15 sec; elongation at
60°C for 1 min. The primer and probe sequences were
designed using Primer Express 3.0 software (Applied Bio-
systems) and all probe sequences were labeled with FAM
at the 5' end and with TAMRA at the 3' end. The following
primer and probe sequences were used: B2M forward (5'-
CAT TCG GGC CGA GAT GTC T-3'), reverse (5'-CTC CAG
GCC AGA AAG AGA GAG TAG-3') and probe (5'-CCG
TGG CCT TAG CTG TGC TCG C-3'); GAPDH forward (5'-
CAC ATG GCC TCC AAG GAG TAA-3'), reverse (5'-TGA
GGG TCT CTC TCT TCC TCT TGT-3') and probe (5'-CTG
GAC CAC CAG CCC CAG CAA G-3'); HMBS forward (5'-
CCA GGG ATT TGC CTC ACC TT-3'), reverse (5'-AAA
GAG ATG AAG CCC CCA CAT-3') and probe (5'-CCT TGA
TGA CTG CCT TGC CTC CTC AG-3'); HPRT1 forward (5'-
GCT CGA GAT GTG ATG AAG GAG AT-3'), reverse (5'-
CCA GCA GGT CAG CAA AGA ATT-3') and probe (5'-CCA
TCA CAT TGT AGC CCT CTG TGT GCT C-3'); SDHA for-
ward (5'-CAC CTA GTG GCT GGG AGC TT-3'), reverse
(5'-GCC CAG TTT TAT CAT CTC ACA AGA-3') and probe
(5'-TGG CAC TTA CCT TTG TCC CTT GCT TCA-3');
NNMT forward (5'-TTG AGG TGA TCT CGC AAA GTT
ATT-3'), reverse (5'-CTC GCC ACC AGG GAG AAA-3')
and probe (5'-CCA CCA TGG CCA ACA ACG AAG GAC-
3'). Expression of NNMT mRNA was measured (the
number of cycles required to achieve a threshold, or CT) in
triplicate, and then normalized relative to a set of refer-
ence genes (B2M, GAPDH, HMBS, HPRT1, and SDHA) by
subtracting the average of the expression of the 5 reference
genes [17]. Using the ΔCT value (NNMT CT - average CT of
reference genes), the mRNA copy number ratio was calcu-
lated as 2-ΔCt. Standard curves were constructed from the
results of simultaneous amplifications of serial dilutions
of the cDNA samples.
Statistical analysis
All statistical analyses were done with the open source sta-
tistical programming environment R http://www.r-
project.org/. Significant differences between gene expres-
sion levels were evaluated by a Student's t test. Correlation
between gene expression and clinicopathologic variables
was evaluated using a χ2 test. Categorical clinicopatho-
logic variables were classified as in another study on HCC
prognosis [18], and continuous clinicopathologic varia-
bles were classified by cutoff values close to their medians
as in other studies [19,20]. For instance, the cutoff value
of 100 ng/ml AFP level has been used in another study
[19], and the cutoff values of 52 and 56 years have been
used in other recent studies [18,20]. Kaplan-Meier sur-
vival curves were calculated using tumor recurrence
(defined as the first appearance of a tumor at any site fol-
lowing definitive treatment) or death as the end points.
The difference of overall survival curve or disease-free sur-
vival curve was examined by log-rank test. In addition, the
Cox proportional hazard regression model was used to
identify independent prognostic factors for overall sur-
vival and disease-free survival. A two-tailed P value test
was used and a P value of < 0.05 was considered statisti-
cally significant.
Results
Expression of NNMT gene in hepatocellular carcinoma
We performed real-time RT-PCR for NNMT mRNA from
frozen paired samples derived from 120 patients with
HCC. A total of 120 HCCs (T) and 40 non-cancerous
hepatic samples (NT) were assessed by real-time RT-PCR.
Expression of NNMT mRNA was measured in triplicate,
and then normalized relative to a set of reference genes
(B2M, GAPDH, HMBS, HPRT1, SDHA) by subtracting the
average of the expression of the 5 reference genes [17].
NNMT mRNA was significantly lower in T than in NT tis-
sues (2.47 vs 35.75; median copy number ratio, P <
0.0001) (Figure 1). The reduced expression of NNMT
mRNA in HCC is consistent with findings of other studies
including research employing microarray measurements
[12-15]. In addition, NNMT mRNA was higher in recur-
rent tumors than in non-recurrent tumors (3.93 vs 1.56;
median copy number ratio, P = 0.21), especially in stage
III & IV tumors (7.26 vs 0.95; median copy number ratio,
P = 0.056), although the differences were not statistically
significant (data not shown).
Relationship between tumor NNMT mRNA level and 
clinicopathologic features
To better understand the significance of NNMT expression
in HCC, we correlated the mRNA expression level with the
major clinicopathologic features. The statistically most
significant cutoff value of NNMT mRNA level discriminat-
ing between patients with a good prognosis and patients
with a poor prognosis was used. As shown in Table 1,
I1 3 1 5
II 30 43
III & IV 5 14
Table 1: Relations between NNMT mRNA levels and clinicopathologic features in HCC (Continued)Journal of Experimental & Clinical Cancer Research 2009, 28:20 http://www.jeccr.com/content/28/1/20
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NNMT expression was significantly associated with tumor
stage (P = 0.010) in 120 HCCs. However, no correlation
was observed between NNMT mRNA level and other clin-
icopathologic parameters (age, gender, virus, liver cirrho-
sis, tumor size, Edmondson grade, and AFP level) (P >
0.05).
Impact of tumor NNMT mRNA levels on OS and DFS
During the follow-up observation period of up to 92
months, locoregional recurrence or distant metastases
occurred in 72 patients (60%) and death was confirmed
in 35 patients (29%). To assess the prognostic significance
of NNMT expression, we analyzed overall survival (OS)
and disease-free survival (DFS) rates using the Kaplan-
Meier method. At the 5-year follow-up, approximately
79% of the patients with low NNMT expression (< 4.40;
copy number ratio) survived, whereas 60% of the patients
with high NNMT expression (≥ 4.40; copy number ratio)
survived (Figure 2A). Similarly, at the 5-year follow-up,
approximately 45% of the patients with low NNMT
expression were disease-free, whereas 22% with high
NNMT expression were disease-free (Figure 2B). The log-
rank test showed that patients who expressed higher
NNMT mRNA levels tended to have a shorter OS time (P
= 0.053) and a significantly shorter DFS time (P = 0.016).
A univariate Cox regression analysis was used to identify
important prognostic factors of OS and DFS. High
Edmondson grade (grade I vs II, P = 0.020; grade I vs III-
IV, P = 0.019), high AFP level (P = 0.0070), large tumor
size (P = 0.00012), and high tumor stage (stage I vs II, P =
0.0068; stage I vs III-IV, P = 2.2 × 10-5) were identified as
important risk factors for OS (Table 2), whereas high
NNMT mRNA level (P = 0.018) and high tumor stage
(stage I vs III-IV, P = 0.0049) were identified as important
risk factors for DFS (Table 3). In a multivariate Cox anal-
ysis, both NNMT expression (P = 0.0096) and tumor stage
III & IV (P = 0.0017) were found to be significant prognos-
tic factors for DFS (Table 4).
Discussion
The metabolism of drugs, toxic chemicals, and hormones
is important in the fields of pharmacology and endo-
crinology given its implication in many pathophysiologi-
cal processes, such as cancer and resistance to
chemotherapy [21]. One of the key enzymes involved in
biotransformation and drug metabolism is NNMT, which
catalyzes the N-methylation of nicotinamide, pyrimi-
dines, and other structural analogues [22,23]. NNMT is
predominantly expressed in the liver, where its activity
varies with a bimodal frequency distribution, thus raising
the possibility that a genetic polymorphism might play a
role in regulating the enzyme activity [23]. Lower expres-
sion is observed in other organs such as the kidney, lungs,
placenta, heart, and brain. Although several studies indi-
cated differential expression of NNMT in HCC [12-15],
the role of NNMT in the molecular pathogenesis of HCC
has yet to be elucidated.
This study focused on NNMT as a potential molecular
marker responsible for determining clinicopathologic fea-
tures and the prognosis of HCC. Utilizing a large number
of HCC specimens, the quantitative real-time PCR assay
showed that the expression of NNMT is markedly reduced
in HCCs compared to non-cancerous surrounding tissues,
consistent with other studies [12-15]. Stratification of
HCC specimens based on NNMT gene expression levels
showed that NNMT expression was significantly corre-
lated with tumor stage (P = 0.010). More importantly, the
log-rank test showed that patients who expressed higher
NNMT mRNA levels tended to have a shorter OS time (P
= 0.053) and a significantly shorter DFS time (P = 0.016).
Both NNMT expression (P = 0.0096) and high tumor
stage (P = 0.0017) were found to be significant prognostic
factors for DFS in a multivariate analysis. It is not clear
why NNMT expression level was a significant prognostic
factor for DFS but not for OS. We believe that the limited
follow-up time was not the main cause of lack of correla-
tion between NNMT and OS because the events (death or
relapse) were rare after the median follow-up time of 50
months in our cohort. Our analysis of NNMT expression
in correlation with the clinicopathologic features and
prognosis of HCC yielded the novel finding that NNMT
mRNA levels could be used as a prognostic factor for DFS.
Box and whiskers plot for NNMT mRNA levels in non-can- cerous liver (NT) and HCC (T) determined by real-time RT- PCR Figure 1
Box and whiskers plot for NNMT mRNA levels in 
non-cancerous liver (NT) and HCC (T) determined 
by real-time RT-PCR. The box is marked by the first and 
third quartile with the median marked by a thick line. The 
whiskers extend to the most extreme data point which is no 
more than 1.5 times the interquartile range from the box.Journal of Experimental & Clinical Cancer Research 2009, 28:20 http://www.jeccr.com/content/28/1/20
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The mechanism for reduced expression of NNMT and its
relation to HCC progression is not clear. Several metal-
lothionein genes involved in detoxification and drug
metabolism are downregulated in HCC especially in
tumors with high Edmonson grades, reflecting de-differ-
entiation of cancer cells [12]. Thus, it is possible that the
liver specific function of NNMT is lost during the progres-
sion of HCC. On the other hand, a recent in vitro study
found that NNMT was necessary for cancer cell migration
in bladder cancer cell lines [24], pointing to a possible
involvement in tumor invasion. In 120 HCCs observed in
this study, NNMT mRNA was higher in recurrent tumors
than in non-recurrent tumors especially in stage III & IV
tumors, although the differences were not statistically sig-
nificant. Thus, there's a possibility that increased NNMT
expression is related to cell mobility and tumor invasive-
ness in high stage HCC. Interestingly, the NNMT expres-
sion level was decreased in stage II tumors compared to
stage I tumors, while stage III & IV tumors showed a sim-
ilar NNMT level as stage I tumors. This could be due to
tumor de-differentiation preceding tumor invasion. How-
ever, we cannot rule out other regulatory mechanisms
independent of tumor de-differentiation and invasion.
In tumors, abnormal expression of NNMT has been
reported in glioblastoma [25], stomach cancer [26,27],
papillary thyroid cancer [28,29], colon cancer [30], and
renal carcinoma [31,32]. NNMT was identified as a novel
serum marker for human colorectal cancers although this
protein is not thought to be secreted [30]. Interestingly,
the upregulation of NNMT was found to be inversely cor-
related with tumor size in renal clear cell carcinoma, sug-
gesting that the enzyme may be significant in an initial
phase of malignant conversion [32]. Increased expression
Table 2: Univariate Cox regression analysis for overall survival
Variable Hazard Ratio 95% Confidence Interval P value
Lower limit Upper limit
Age
(< 55 years vs ≥ 55 years)
0.76 0.38 1.53 0.45
Gender
(male vs female)
1.00 0.46 2.21 1.00
Edmondson grade
(I vs II)
5.51 1.31 23.2 0.02
Edmondson grade
(I vs III – IV)
6.53 1.36 31.4 0.019
HbsAg
(absent vs present)
1.49 0.58 3.83 0.41
HCV
(absent vs present)
2.06 0.73 5.87 0.17
AFP level
(< 100 ng/ml vs ≥ 100 ng/ml)
2.67 1.31 5.46 0.0070
Liver cirrhosis
(absent vs present)
1.50 0.77 2.93 0.23
Tumor size
(< 5 cm vs ≥ 5 cm)
4.07 1.99 8.31 0.00012
Tumor stage
(I vs II)
7.81 1.76 34.6 0.0068
Tumor stage
(I vs III – IV)
23.5 5.48 100.9 2.2 × 10-5
NNMT
(low vs high)
1.91 0.98 3.71 0.057Journal of Experimental & Clinical Cancer Research 2009, 28:20 http://www.jeccr.com/content/28/1/20
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of NNMT in non-tumor cells was reported in a few situa-
tions: the cerebellum of patients with Parkinson's disease
[33,34], human hepatoma cells (Huh7) with expression
of the hepatitis C core protein [35], and the liver of mice
transplanted with tumors [36,37]. In these situations, the
mechanism for deregulated NNMT expression remains
unclear.
Recently, NNMT promoter was cloned and studied in pap-
illary thyroid cancer cell lines, where it was shown to be
activated by hepatocyte nuclear factor-1β [29]. Subse-
quently, it was found that the NNMT promoter region
also contains the consensus sequences for signal transduc-
ers and activators of transcription (STAT) binding ele-
ments and nuclear factor-interleukin (IL) 6 binding
elements [38]. Accordingly, hepatoma cell line (Hep-G2),
which expressed low levels of NNMT, increased NNMT
expression several fold upon stimulation by IL-6. The
stimulation by IL-6 was largely abolished with the expres-
sion of dominant-negative STAT3 [38]. Activation of
STAT3 alone caused a four-fold higher induction of
NNMT promoter activity in the transformed Hep-G2 cells.
Thus, NNMT expression could be regulated by IL-6 and
STAT3 in a subclass of HCC. The expression of NNMT
analyzed in relation to the expression of related regulatory
molecules could improve the predictive power on HCC
prognosis.
To our knowledge, this is the first report of NNMT as a
prognostic factor of DFS in HCC. The findings herein indi-
cate that NNMT is an attractive target for therapeutic reg-
ulation because it is involved in drug metabolism and
could alter the efficacy of standard chemotherapeutic
drugs. Additional research in larger populations of HCC
Table 3: Univariate Cox regression analysis for disease-free survival
Variable Hazard Ratio 95% Confidence Interval P value
Lower limit Upper limit
Age
(< 55 years vs ≥ 55 years)
0.80 0.50 1.27 0.34
Gender
(male vs female)
1.02 0.60 1.73 0.95
Edmondson grade
(I vs II)
1.25 0.72 2.17 0.43
Edmondson grade
(I vs III – IV)
1.08 0.50 2.30 0.85
HbsAg
(absent vs present)
1.02 0.58 1.80 0.94
HCV
(absent vs present)
2.11 0.97 4.60 0.061
AFP level
(< 100 ng/ml vs ≥ 100 ng/ml)
1.19 0.76 1.86 0.45
Liver cirrhosis
(absent vs present)
1.14 0.73 1.78 0.57
Tumor size
(< 5 cm vs ≥ 5 cm)
1.30 0.82 2.04 0.26
Tumor stage
(I vs II)
1.10 0.64 1.89 0.72
Tumor stage
(I vs III – IV)
2.22 1.27 3.87 0.0049
NNMT
(low vs high)
1.72 1.10 2.70 0.018Journal of Experimental & Clinical Cancer Research 2009, 28:20 http://www.jeccr.com/content/28/1/20
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patients may ultimately determine the ability of NNMT in
accurate diagnosis and sub-classification of HCC.
Conclusion
We found that NNMT was associated with the tumor stage
and that higher NNMT mRNA levels in HCC was signifi-
cantly associated with shorter DFS time. It is very impor-
tant to develop new target molecules and to establish
novel chemotherapy strategies in malignancies such as
HCC, which shows frequent relapse and high mortality
despite various treatment modalities. The broad substrate
specificity of NNMT suggests that it could alter the efficacy
and/or adverse effect of standard doses of chemothera-
peutic drugs. Therefore, NNMT merits further study for its
role as a prognostic factor of OS and DFS with a larger
cohort of HCC patients. Moreover, NNMT itself could be
a target for chemotherapeutic agents. Establishing the
molecular interactions of NNMT with diverse molecular
pathogenic factors in HCC will enable new studies and
development of effective therapeutic regimens.
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